National Institute on Drug Abuse
Director's Report to the National Advisory Council on Drug Abuse
February, 1999
Publications
Research Monographs
Drug Abuse Prevention Through Family InterventionÑRM 177--NCADI #M177
NIH Pub. No. 99-4135
This monograph is based on a scientific meeting that was sponsored by NIDA. It consists of scientific papers presented at the meeting on state-of-the-art family-based drug abuse prevention research; synopses of panel and workshop discussions; and recommendations for future NIDA research in the area of family focused drug abuse prevention interventions.
Other Publications
Epidemiologic Trends in Drug Abuse: Community Epidemiology Work Group, June 1998: Volume II -- NIH Pub. No. 99-4301
NIDA Community Drug Alert Bulletin - Methamphetamine -- NCADI MS709
NIDA NOTES, Vol. 13, Issue No. 4 -- NCADI NN0032
The lead story for this issue is about the cost to society of drug abuse. Two articles discuss gender differences in drug abuse and in HIV prevention efforts. The Director's Column discusses the importance of tailoring intervention efforts to include gender as a component of the interventions. The affect of prenatal cocaine exposure on elementary-children is the subject of another article. Winners of the Prism Awards and increased neuroscience research in NIDA's Division of Intramural Research were also covered.
Preston, K.L., and Walsh, S.L. Evaluating Abuse Liability: Methods and Predictive Value. In: Drug Abuse Handbook, ed. by S. B. Karch, CRC Press LLC, Boca Raton, FL, pp. 276-306, 1998.
Shoaib, M., Swanner, L.S., Beyer, C.E., Goldberg, S.R. and Schindler, C.W. The GABAB Agonist Baclofen Modifies Cocaine Self-administration in Rats. Behavioral Pharmacology, 9, pp. 195-206, 1998.
Hoffman, J.A., and Moolchan E.T. The Phases of Treatment Model of Methadone Treatment. Euro-Methwork, 13, pp. 7-9, 1998.
Radzius A., Gorelick, D.A., and Henningfield, J.E. Cigarette Smoking During Early Cocaine Abstinence. The American Journal on Addictions, 7(4), pp. 305-308, 1998.
Huestis, M.A. and Cone, E. Alternative Testing Matrices. In Karch, S. (ed.) Handbook of Drug Abuse, CRC Press, (Boca Raton, FL), pp. 799-857, 1998.
Huestis, M.A., and Cone, E. Urinary Excretion Half-life of 11-Nor-9-carboxy-D9- tetrahydrocannabinol in Humans. Therapeutic Drug Monitoring, 20, pp. 570-576, 1998.
Huestis, M.A., and Cone, E. Differentiating New Marijuana Use From Residual Drug
Excretion in Occasional Marijuana Users. Journal of Analytical Toxicology, 22, pp. 445-454, 1998.
Cone, E.J., Tsadik, A., Oyler, J. and Darwin, W.D. Cocaine Metabolism and Urinary Excretion Following Different Routes of Administration. Therapeutic Drug Monitoring, 20, pp. 556-560, 1998.
Cone, E.J., Lange, R., and Darwin, W.D. In Vivo Adulteration: Excess Fluid Ingestion Causes False Negative Marijuana and Cocaine Urine Test Results. Journal of Analytical Toxicology, 22, pp. 460-473, 1998.
Soderstrom, C.A., Dischinger, P.C., Kerns, T.J., Kufera, J.A., McDuff, D.R., Gorelick, D.A, and Smith, G.S. Screening Trauma Patients for Alcoholism According to NIAAA Guidelines with Alcohol Use Disorders Identification Test Questions. Alcoholism: Clinical and Experimental Research, 22, pp. 1470-1475, 1998.
Radzius, A., Gorelick, D.A., and Henningfield, J.E. Cigarette Smoking during Early Cocaine Abstinence. American Journal on Addictions, 7, pp. 305-308, 1998.
Singleton, E.G. and Gorelick, D.A. Mechanisms of Alcohol Craving and their Clinical Implications. In Galanter, M. (Ed.), Recent Developments in Alcoholism, Vol 14, (New York, Plenum), pp. 177-195, 1998.
Gorelick, D.A., Pickens, R.W., and Bonkovsky, F.O. Clinical Research in Substance Abuse: Human Subjects Issues. In Pincus, H.A., Lieberman, J.A., and Ferris, S. (Eds.), Ethics in Psychiatric Research: A Resource Manual for Human Subjects Protection, (Washington, D.C., American Psychiatric Association), pp. 177-218, 1998.
Gorelick, D.A. Pharmacologic Therapies for Cocaine and Other Stimulant Addiction. In Graham, A.W. and Schultz, T.K. (Eds.), Principles of Addiction Medicine, 2nd edition, (Chevy Chase, MD: American Society of Addiction Medicine), pp. 531-544, 1998.
Wilkins, J.N., Gorelick, D.A., and Conner, B.T. Pharmacologic Therapies for Other Drugs and Multiple Drug Addiction. In Graham, A.W. and Schultz, T.K. (Eds.), Principles of Addiction Medicine, 2nd edition, (Chevy Chase, MD: American Society of Addiction Medicine), pp. 583-592, 1998.
Wilkins, J.N., Conner, B.T., and Gorelick, D.A. Management of Stimulant, Hallucinogen, Marijuana and Phencyclidine Intoxication and Withdrawal. In Graham, A.W. and Schultz, T.K. (Eds.), Principles of Addiction Medicine, 2nd edition, (Chevy Chase, MD: American Society of Addiction Medicine), pp. 465-486, 1998.
Liu, X., Matochik, J.A., Cadet, J.L., and London, E.D. Smaller Volume of Prefrontal Lobe in Polysubstance Abusers: A Magnetic Resonance Imaging Study. Neuropsychopharmacology, 18, pp. 243-252, 1998.
Subramaniam, J., Ladenheim, B., and Cadet, J.L. Methamphetamine-induced Changes in Antioxidant Enzymes and Lipid Peroxidation in Copper/Zinc-Superoxide Dismutase Transgenic Mice. Annals of NY Academy of Science, 844, pp. 92-102, 1998.
Asanuma, M., Hirata, H., and Cadet, J.L. Attenuation of 6-hydroxydopamine-induced Dopaminergic Nigrostriatal Lesions in Superoxide Dismutase Transgenic Mice. Neuroscience, 85, pp. 907-917, 1998.
Hirata, H., Asanuma, M., and Cadet, J.L. Melatonin Attenuates Methamphetamine-induced Toxic Effects on Dopamine and Serotonin Terminals in Mouse Brain. Synapse, 30, pp. 150-155, 1998.
Hirata, H., Asanuma, M., and Cadet, J.L. Superoxide Radicals are Mediators of the Effects of Methamphetamine on ZIF 268 (Egr-1, NGFI-A) in the Brain: Evidence from Using CuZn Superoxide Dismutase Transgenic Mice. Molecular Brain Research, 58, pp. 209-216, 1998.
Vawter, M.P., Hemperly, J.J., Thomas, M.H., Bachus, S.E., VanderPutten, D.M., Howard, A.L., Cannon-Spoor, H.E., McCoy, M.T., Webster, M.J., Kleinman, J.E., and Freed, W.J. VASE-containing N-CAM Isoforms are Increased in the Hippocampus in Bipolar Disorder but not Schizophrenia. Experimental Neurology, 154, pp. 1-11, 1998.
Bergman, J. and Katz, J.L. Behavioral Pharmacology of Cocaine. In: Higgins, S.T. and Katz, J.L. (Eds.). Cocaine Abuse Research: Pharmacology, Behavior, and Clinical Applications. San Diego: Academic Press, pp. 51-79, 1998.
Higgins, S.T. and Katz, J.L. (Eds.) Cocaine Abuse Research: Pharmacology, Behavior, and Clinical Applications. San Diego: Academic Press, 1998.
Husbands, S.M., Kline, R.H., Allen, A.C., and Newman, A.H. A Diastereospecific Synthesis of 2-Methyl-5-b-phenyl-5-a-carboethoxy-2-azabicyclo[2.2.1]heptane: A Ring Constrained Analog of Meperidine. J. Org. Chem., 63, pp. 418-419, 1998.
Lomenzo, S.A., Izenwasser, S., Katz, J.L., and Trudell, M.L. The Effects of Alkyl Substituents at the 6-position of Cocaine Analogues on Dopamine Transporter Binding Affinity and Dopamine Uptake Inhibition. In: Newman, A.H. (Ed.) The Dopamine Transporter as a Molecular Target for the Development of Cocaine Abuse Therapeutics, Medicinal Chemistry Research, 8, pp. 35-42, 1998.
Newman, A.H. Novel Dopamine Transporter Ligands: The State of the Art. Med. Chem. Res., 8, pp. 1-11, 1998. (Invited Guest Editorial - Special Issue).
Newman, A.H., and Agoston, G.E. Novel Benztropine [3?-(Diphenylmethoxy)tropane] Analogs as Probes for the Dopamine Transporter. Current Medicinal Chemistry, 5, pp. 301-315, 1998. (Invited Review).
Zhang, C., Izenwasser, S., Katz, J.L., Terry, P., and Trudell, M.L. Synthesis and Dopamine Transporter Affinity of the Four Stereoisomers of (")-2-methoxycarbonyl-7-methyl-3-phenyl- 7-azabicyclo[2.2.1] heptane. Journal of Medicinal Chemistry, 41, pp. 2430-2435, 1998.
Women, Drug Use, and HIV Infection (Haworth Press, 1998). Edited by Sally J. Stevens, Stephanie Tortu, and Susan L. Coyle. This volume, co-published simultaneously as Women & Health, Vol. 27, Numbers 1-2, brings together 13 papers from NIDA's Cooperative Agreement for AIDS Community-Based Outreach/Intervention Research Program. Cooperative Agreement data are presented at the local and national level and examine women's individual HIV risks as well as social/contextual variables that affect risk taking behaviors.
Coyle, S.L., Needle, R.H., Normand, J. Outreach-Based HIV Prevention for Injecting Drug Users: A Review of Published Outcome Data. Public Health Reports, 113 (Supp. 1), pp. 19-30, 1998.
Needle, R.H., Coyle, S.L., Normand, J., Lambert, E., Cesari, H. HIV Prevention with Drug-Using Populations--Current Status and Future Prospects: Introduction and Overview. Public Health Reports, 113 (Supp. 1), pp. 4-18, 1998.
Cost-Benefit and Cost-Effectiveness Analysis of Drug Abuse Treatment Services. The foundations of cost-benefit and cost-effectiveness analysis (CB/CEA) for drug abuse treatments are developed. An economic model of addict choice and drug markets is presented. This model is synthesized with the current "cost-of-illness" methods used to measure the burden of the disease on society. The problem of doing cost-effectiveness studies in the presence of large nonhealth benefits is examined, and guidance is offered to clinical studies with a cost-effectiveness component or to stand alone cost-effectiveness studies. References and an extensive bibliography on drug abuse treatment related CB/CEA studies are appended. Cartwright, W.S. Evaluation Review, 22(5), pp. 609-636, 1998.
For additional information about NIDA send e-mail to Information@nida.nih.gov
[NIDA Home Page][Office
of the Director][Report Index][Previous
Report Section] [Next Report Section]
|
